摘要
目的探讨分析阿托伐他汀对冠状动脉介入术患者急性肾损伤的预防作用。方法在我院收治的急性冠脉综合征患者(入院时间:2016年2月—2019年2月)中抽取60例作为本次研究对象,按照随机数字表法将入组患者分为对照组(n=30)与研究组(n=30),对照组患者于术前口服20 mg阿托伐他汀钙片,并于术后连续3 d每日口服20 mg,研究组患者于术前口服80 mg阿托伐他汀钙片,并于术后连续3 d每日口服40 mg,比较2组治疗前后uL-FABP、sCr、uKIM-1、uNGAL等指标水平及CIAKI发生情况。结果两组术前各指标水平差异比较基本一致,无统计学意义(P>0.05);术后24 h、48 h各指标水平研究组均低于对照组(P<0.05),差异无统计学意义;研究组CIAKI发生例数为1例,对照组3例,两组CIAKI发生率差异比较无统计学意义(P>0.05)。结论给予急性冠脉综合征PCI患者阿托伐他汀治疗有利于改善术后急性肾损伤的严重程度,安全性良好。
Objective To investigate the preventive effect of atorvastatin on acute kidney injury in patients undergoing coronary intervention.Methods Sixty patients with acute coronary syndrome admitted to our hospital(admission time:February 2016 to February 2019)were enrolled in this study.The patients were divided into control group according to the random number table method.(n=30)and the study group(n=30),the control group received 20 mg of atorvastatin calcium tablets before surgery and orally 20 mg daily for 3 consecutive days after surgery.The study group received 80 mg orally before surgery.The atorvastatin calcium tablets were orally administered 40 mg daily for 3 consecutive days.The levels of uLFABP,sCr,uKIM-1,uNGAL and CIAKI were compared before and after treatment.Results The differences of the indexes of the two groups before operation were basically the same,and there was no statistical significance(P>0.05).At 24 h and 48 h after operation,the index levels of the study group were lower than those of the control group(P<0.05),and the difference was not statistically significant.;There were 1 case of CIAKI in the study group and 3 cases in the control group.There was no significant difference in the incidence of CIAKI between the two groups(P>0.05).Conclusion Atorvastatin in patients with acute coronary syndrome is beneficial to improve the severity of postoperative acute kidney injury and has good safety.
作者
孙可可
SUN Keke(Department of Cardiology,Jurong People's Hospital,Jurong Jiangsu 212400,China)
出处
《中国继续医学教育》
2020年第1期122-124,共3页
China Continuing Medical Education
